• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Janux Therapeutics Inc.

    2/27/25 4:55:48 PM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $JANX alert in real time by email
    S-8 1 janx-20250227.htm S-8 S-8

     

    As filed with the Securities and Exchange Commission on February 27, 2025

    Registration No. 333-

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    Form S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

    Janux Therapeutics, Inc.

    (Exact name of registrant as specified in its charter)

     

     

    Delaware

    82-2289112

    (State or other jurisdiction of

    incorporation or organization)

    (IRS employer

    identification number)

     

     

    10955 Vista Sorrento Parkway, Suite 200, San Diego, California

    92130

    (Address of Principal Executive Offices)

    (Zip Code)

    2021 Equity Incentive Plan

    2021 Employee Stock Purchase Plan

    (Full titles of the plans)

    David Campbell, Ph.D.

    President and Chief Executive Officer

    Janux Therapeutics, Inc.

    10955 Vista Sorrento Parkway, Suite 200

    San Diego, California 92130

    (858) 751-4493

    (Name, address, including zip code and telephone number, including area code, of agent for service)

    Copies to:

    Kenneth J. Rollins, Esq.

    Edmond J. Lay, Esq.

    Cooley LLP

    10265 Science Center Drive

    San Diego, California 92121

    (858) 550-6000

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer

    ☒

    Accelerated filer

    ☐

    Non-accelerated filer

    ☐

    Smaller reporting company

    ☐

    Emerging growth company

    ☐

     

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     


     

    EXPLANATORY NOTE

    The Registrant is filing this Registration Statement on Form S-8 for the purpose of registering an additional 2,953,230 shares of common stock under the Janux Therapeutics, Inc. 2021 Equity Incentive Plan and an additional 590,646 shares of common stock under the Janux Therapeutics, Inc. 2021 Employee Stock Purchase Plan, pursuant to the provisions of each plan which provide for annual automatic increases in the number of shares of common stock reserved for issuance under each respective plan.

    INCORPORATION OF DOCUMENTS BY REFERENCE

    This Registration Statement is being filed for the purpose of increasing the number of securities of the same class as other securities for which a Registration Statement of the Registrant on Form S-8 relating to the same employee benefit plan is effective.

    The Registrant previously registered shares of common stock for issuance under its 2021 Equity Incentive Plan and its 2021 Employee Stock Purchase Plan under Registration Statements on Form S-8, filed with the Securities and Exchange Commission on June 11, 2021 (File No. 333-257039), March 18, 2022 (File No. 333-263712), March 10, 2023 (File No. 333-270470) and March 8, 2024 (File No. 333-277797).

    Pursuant to General Instruction E to Form S-8, this Registration Statement hereby incorporates by reference the contents of the Registration Statement referenced above.

    Item 8. Exhibits.

    The exhibits to this Registration Statement are listed below:

     

    Exhibit
    Number

    Exhibit Description

     

     

    4.1

    Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, filed with the SEC on June 15, 2021).

     

     

    4.2

    Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K, filed with the SEC on June 15, 2021).

     

     

    4.3

    Form of Common Stock Certificate of the Registrant (incorporated by reference to Exhibit 4.1 to the Registrant’s Registration Statement on Form S-1 (File No. 333-256297), as amended, filed with the SEC on June 7, 2021).

     

     

     

    5.1

     

    Opinion of Cooley LLP.

     

     

     

    23.1

     

    Consent of Independent Registered Public Accounting Firm.

     

     

     

    23.2

     

    Consent of Cooley LLP (included in Exhibit 5.1).

     

     

     

    24.1

     

    Power of Attorney (included on the signature page to this Registration Statement).

     

     

     

    99.1

     

    Janux Therapeutics, Inc. 2021 Equity Incentive Plan, Forms of Option Grant Notice, Option Agreement and Notice of Exercise thereunder, and Forms of RSU Award Grant Notice and RSU Award Agreement. (incorporated by reference to Exhibit 10.1 to the Registrant’s Quarterly Report on Form 10-Q, filed with the SEC on August 7, 2024).

     

     

     

    99.2

     

    Janux Therapeutics, Inc. 2021 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.4 to the Registrant’s Registration Statement on Form S-1 (File No. 333-256297), as amended, filed with the SEC on June 7, 2021).

     

     

     

    107

     

    Filing Fee Table.

     

     


     

    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Diego, State of California, on February 27, 2025.

    JANUX THERAPEUTICS, INC.

    Date: February 27, 2025

    By:

    /s/ David Campbell, Ph.D.

    David Campbell, Ph.D.

    President and Chief Executive Officer

    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints David Campbell and Maria Dobek, and each of them, as his or her true and lawful attorneys-in-fact and agents, each with the full power of substitution, for him or her and in his or her name, place or stead, in any and all capacities, to sign any and all amendments to this registration statement (including post-effective amendments), and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement on Form S-8 has been signed by the following persons in the capacities and on the dates indicated.

    Name

    Title

    Date

    /s/ David Campbell, Ph.D.

    President and Chief Executive Officer and Director

    February 27, 2025

    David Campbell, Ph.D.

    (Principal Executive and Financial Officer)

    /s/ Maria Dobek

     

    Vice President, Accounting

     

    February 27, 2025

    Maria Dobek

     

    (Principal Accounting Officer)

     

     

     

     

     

     

     

    /s/ Ron Barrett, Ph.D.

     

    Chairperson of the Board of Directors

     

    February 27, 2025

    Ron Barrett, Ph.D.

     

     

     

     

     

     

     

     

     

    /s/ Vickie Capps

    Director

    February 27, 2025

    Vickie Capps

    /s/ Eric Dobmeier

     

    Director

     

    February 27, 2025

    Eric Dobmeier

     

     

     

     

     

     

     

     

     

    /s/ Sheila Gujrathi, M.D.

    Director

    February 27, 2025

    Sheila Gujrathi, M.D.

    /s/ Natasha Hernday

     

    Director

     

    February 27, 2025

    Natasha Hernday

     

     

     

     

     

     

     

     

     

    /s/ Winston Kung

    Director

    February 27, 2025

    Winston Kung

    /s/ Alana McNulty

     

    Director

     

    February 27, 2025

    Alana McNulty

     

     

     

     

     

     

     

     

     

    /s/ Jake Simson, Ph.D.

    Director

    February 27, 2025

    Jake Simson, Ph.D.

     

     

     


    Get the next $JANX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $JANX

    DatePrice TargetRatingAnalyst
    12/3/2024$82.00 → $100.00Buy
    BTIG Research
    12/3/2024$63.00 → $70.00Buy
    H.C. Wainwright
    11/22/2024$79.00Outperform
    Leerink Partners
    10/24/2024$69.00Buy
    UBS
    9/6/2024$70.00Buy
    Stifel
    5/30/2024$47.00Sector Perform
    Scotiabank
    3/21/2024$62.00Buy
    BTIG Research
    3/20/2024$100.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $JANX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Janux Therapeutics Inc.

      SC 13G/A - Janux Therapeutics, Inc. (0001817713) (Subject)

      11/14/24 4:24:38 PM ET
      $JANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Janux Therapeutics Inc.

      SC 13G/A - Janux Therapeutics, Inc. (0001817713) (Subject)

      11/14/24 4:17:06 PM ET
      $JANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Janux Therapeutics Inc.

      SC 13G/A - Janux Therapeutics, Inc. (0001817713) (Subject)

      11/14/24 4:01:49 PM ET
      $JANX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JANX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Janux Therapeutics Appoints Janeen Doyle as Chief Corporate and Business Development Officer

      Ms. Doyle brings more than two decades of corporate strategy and business development experience across biotech, pharma, and venture ecosystems Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the appointment of Janeen Doyle, MBA, as Chief Corporate and Business Development Officer. "Janeen's unique blend of corporate development, strategic execution, and clinical insight makes her an ideal leader to help drive the next phase of growth at J

      5/15/25 8:00:00 AM ET
      $JANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Janux Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights

      Phase 1b expansion study initiated with JANX007 in taxane-naïve mCRPC patients Updated JANX007 data from Phase 1a dose escalation support initiation of Phase 1b dose expansion Enrollment ongoing for JANX007 and JANX008 Updates on JANX007 and JANX008 expected in the second half of 2025 $1.01 billion in cash, cash equivalents, and short-term investments at end of first quarter 2025 Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today reported fina

      5/8/25 4:01:00 PM ET
      $JANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Janux Therapeutics Initiates Phase 1b Expansion Studies with JANX007 in Patients with Prostate Cancer and Provides Program Updates

      Phase 1b expansion study initiated in taxane-naïve mCRPC patients Updated data from Phase 1a dose escalation support initiation of Phase 1b dose expansion Updates on JANX007 and JANX008 expected in the second half of 2025 Janux to host R&D Day in mid-2025 highlighting preclinical pipeline progression to the clinic Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the initiation of Phase 1b expansion studies in the ongoing ENGAGER-PSMA

      5/5/25 8:30:00 AM ET
      $JANX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JANX
    Leadership Updates

    Live Leadership Updates

    See more
    • Janux Therapeutics Appoints Janeen Doyle as Chief Corporate and Business Development Officer

      Ms. Doyle brings more than two decades of corporate strategy and business development experience across biotech, pharma, and venture ecosystems Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the appointment of Janeen Doyle, MBA, as Chief Corporate and Business Development Officer. "Janeen's unique blend of corporate development, strategic execution, and clinical insight makes her an ideal leader to help drive the next phase of growth at J

      5/15/25 8:00:00 AM ET
      $JANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Janux Therapeutics Promotes Zachariah McIver, D.O., Ph.D. to Chief Medical Officer

      Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the promotion of Dr. Zachariah McIver to Chief Medical Officer. "The appointment of Zach to CMO is an important milestone for Janux. Zach's expertise in T cell engagers has brought significant value to our organization and he has been essential in our efforts to optimize the clinical development of our PSMA-TRACTr and clinical pipeline," said David Campbell, Ph.D., President and CEO of Janux.

      1/24/25 4:01:00 PM ET
      $JANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Janux Therapeutics Announces Updates to Board of Directors

      The appointment of Eric Dobmeier and Natasha Hernday to the Board brings extensive operational and business development experience to support corporate and pipeline strategy Janux also announced the resignation of Jay Lichter, Ph.D., from the Board, and the appointment of current Board member Ronald W. Barrett, Ph.D., as Chairperson Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the appointment of Eric Dobmeier and Natasha Hernday to

      7/22/24 4:01:00 PM ET
      $JANX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JANX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BTIG Research reiterated coverage on Janux Therapeutics with a new price target

      BTIG Research reiterated coverage of Janux Therapeutics with a rating of Buy and set a new price target of $100.00 from $82.00 previously

      12/3/24 7:52:53 AM ET
      $JANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright reiterated coverage on Janux Therapeutics with a new price target

      H.C. Wainwright reiterated coverage of Janux Therapeutics with a rating of Buy and set a new price target of $70.00 from $63.00 previously

      12/3/24 7:50:21 AM ET
      $JANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Leerink Partners initiated coverage on Janux Therapeutics with a new price target

      Leerink Partners initiated coverage of Janux Therapeutics with a rating of Outperform and set a new price target of $79.00

      11/22/24 7:48:26 AM ET
      $JANX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JANX
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Janux Therapeutics Inc.

      SCHEDULE 13G/A - Janux Therapeutics, Inc. (0001817713) (Subject)

      5/14/25 12:25:43 PM ET
      $JANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Janux Therapeutics Inc.

      10-Q - Janux Therapeutics, Inc. (0001817713) (Filer)

      5/8/25 4:30:38 PM ET
      $JANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Janux Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Janux Therapeutics, Inc. (0001817713) (Filer)

      5/8/25 4:12:38 PM ET
      $JANX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JANX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Business Officer Meyer Andrew Hollman exercised 3,333 shares at a strike of $4.21 and sold $106,745 worth of shares (3,333 units at $32.03) (SEC Form 4)

      4 - Janux Therapeutics, Inc. (0001817713) (Issuer)

      5/2/25 8:00:06 PM ET
      $JANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Business Officer Meyer Andrew Hollman exercised 3,334 shares at a strike of $4.21 and sold $100,020 worth of shares (3,334 units at $30.00) (SEC Form 4)

      4 - Janux Therapeutics, Inc. (0001817713) (Issuer)

      4/23/25 8:00:05 PM ET
      $JANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ra Capital Management, L.P. bought $25,342,965 worth of shares (824,041 units at $30.75) (SEC Form 4)

      4 - Janux Therapeutics, Inc. (0001817713) (Issuer)

      3/7/25 6:05:32 PM ET
      $JANX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JANX
    Financials

    Live finance-specific insights

    See more
    • Janux Therapeutics Announces Positive Interim Clinical Data from Phase 1a Dose Escalation for PSMA-TRACTr JANX007 and an Update on Pipeline Programs

      Multiple patients treated with PSMA-TRACTr JANX007 have achieved meaningful PSA drops coupled with manageable safety and CRS PSMA-TRACTr JANX007 and EGFR-TRACTr JANX008 have been generally well tolerated at levels above the projected maximum tolerable dose of the parental T cell engagers JANX007 preliminary data showed encouraging safety results consistent with on-tumor activity with no dose-limiting toxicities PK exposure demonstrated TRACTr activation with lack of TCE accumulation No treatment-emergent ADA titers observed Janux to host virtual investor event today at 4:00 PM Eastern Time Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutica

      7/17/23 8:00:00 AM ET
      $JANX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JANX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Ra Capital Management, L.P. bought $25,342,965 worth of shares (824,041 units at $30.75) (SEC Form 4)

      4 - Janux Therapeutics, Inc. (0001817713) (Issuer)

      3/7/25 6:05:32 PM ET
      $JANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ra Capital Management, L.P. bought $53,700,000 worth of shares (1,200,000 units at $44.75) (SEC Form 4)

      4 - Janux Therapeutics, Inc. (0001817713) (Issuer)

      10/22/24 4:20:04 PM ET
      $JANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Reardon Tighe bought $4,988,643 worth of shares (849,854 units at $5.87) (SEC Form 4)

      4 - Janux Therapeutics, Inc. (0001817713) (Issuer)

      11/15/23 4:48:17 PM ET
      $JANX
      Biotechnology: Pharmaceutical Preparations
      Health Care